| Date | Title | Description | |
|---|---|---|---|
| 21 Oct 2025 | On business and financial situation | The Company releases the press release in relation to the announcement of the collaboration with Roche for the manufacture of a new medicine in development | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 24 Jul 2025 | On P&L | The Company releases the press release related to the first half of 2025 financial results | Download |
| 24 Jul 2025 | On P&L | The Company releases the first half 2025 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 25 Feb 2026 | Annual Corporate Governance Report | The Company submits the Annual Corporate Governance Report for fiscal year 2025. | Download |
| 25 Feb 2026 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2025 annual report regarding remuneration of the members of the Board of Directors. | Download |
| 18 Nov 2025 | On business and financial situation | The Company releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development | Download |
| 02 Oct 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2025 | Download |
| 04 Jul 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2025 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Apr 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2019 | Download |
| 19 Mar 2019 | R&D: new licenses, patents and registered trademarks | ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia | Download |
| 26 Feb 2019 | Informe Anual de Remuneraciones de los Consejeros | ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors | Download |
| 26 Feb 2019 | Informe Anual de Gobierno Corporativo | ROVI releases the 2018 Annual Corporate Governance Report | Download |
| 26 Feb 2019 | Otros sobre gobierno corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |